• Ipsen SA, of Paris, reported results from the primary endpoint of the CLARINET study, which is testing the effect of Somatuline Autogel 120 mg on tumor progression-free survival in patients with gastrointestinal and pancreatic neuroendocrine tumors (GEP-NETs), showing that treatment with Somatuline was found to be statistically significantly superior to placebo in extending time to either disease progression or death. The 96-week CLARINET study enrolled patients with well or moderately differentiated nonfunctioning GEP-NETs and a proliferation index of less than 10 percent.